<DOC>
	<DOCNO>NCT01957644</DOCNO>
	<brief_summary>To investigate maximum tolerate dose ( MTD ) , safety , pharmacokinetics , efficacy volasertib combination azacitidine patient myelodysplastic syndrome ( MDS ) chronic myelomonocytic leukemia ( CMML ) candidate hematopoietic stem cell transplant</brief_summary>
	<brief_title>Phase I Dose Escalation Trial Volasertib Combination With Azacitidine Patients With MDS CMML</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Inclusion criterion : Adult patient previously untreated , intermediate2 high risk MDS CMML eligible hematopoietic stem cell transplantation ( HSCT ) base documented patient characteristic like age , performance status , concomitant diagnosis , organ dysfunction Further inclusion criterion apply Exclusion criterion : Prior concomitant therapy high risk MDS ( example , limited , hypomethylating agent like azacitidine ) . Note : Prior treatment EPO allow &gt; 1 week treatment study medication . Patients must receive MDS therapy since diagnosis higherrisk MDS . However , previous lenalidomide treatment could administer lowerrisk MDS treatment long therapy discontinue least &gt; 4 week initiation current study treatment . Treatment investigational drug within 2 week first administration present trial drug within less 5 half life investigational drug treatment present trial drug , whichever longer . Second malignancy currently require active therapy ( except hormonal/antihormonal treatment , e.g . prostate breast cancer ) . Corrected QT interval accord Friederica ( QTcF ) prolongation &gt; 470 m QT prolongation deem clinically relevant investigator ( e.g. , congenital long QT syndrome ) .The QTcF calculate mean 3 Electrocardiograms ( ECGs ) take screening . Total bilirubin &gt; 1.5 x upper limit normal related Gilberts disease , hemolysis , secondary MDS . Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) &gt; 2.5 x upper limit normal ( ULN ) Creatinine &gt; 1.5 x ULN Active hepatitis B hepatitis C , laboratory evidence chronic infection ( hepatitis test result do routine diagnostics acceptable do within 14 day first study treatment dose ) . HIV infection ( HIV test result routine diagnostics acceptable do within 14 day first study treatment dose ) . Severe illness organ dysfunction involve kidney , liver organ system ( e.g . active uncontrolled infection , unstable angina pectoris history severe congestive heart failure , clinically unstable cardiac disease pulmonary disease ) , opinion investigator would interfere evaluation safety study treatment Further exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>